End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.35 TWD | +0.15% | +1.03% | -8.40% |
Mar. 13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2021 | 110M 3.37M | Sales 2022 | 188M 5.79M | Capitalization | 4.02B 124M |
---|---|---|---|---|---|
Net income 2021 | -47M -1.44M | Net income 2022 | -248M -7.62M | EV / Sales 2021 | 18.4 x |
Net cash position 2021 | 342M 10.5M | Net cash position 2022 | 457M 14.05M | EV / Sales 2022 | 18.9 x |
P/E ratio 2021 |
-49.9
x | P/E ratio 2022 |
-15.7
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 31.48% |
1 day | +0.15% | ||
1 week | +1.03% | ||
Current month | +1.18% | ||
1 month | +3.00% | ||
3 months | -9.96% | ||
6 months | -5.50% | ||
Current year | -8.40% |
Managers | Title | Age | Since |
---|---|---|---|
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
Ching Fen Yang
CTO | Chief Tech/Sci/R&D Officer | - | 14-07-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chung Chi Li
BRD | Director/Board Member | - | 20-06-16 |
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 34.35 | +0.15% | 29 936 |
24-04-24 | 34.3 | +0.59% | 51,069 |
24-04-23 | 34.1 | -0.44% | 42,956 |
24-04-22 | 34.25 | +3.32% | 70,358 |
24-04-19 | 33.15 | -0.75% | 51,911 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-8.40% | 69.11M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- 6564 Stock